It will be of considerable importance to determine whether CLP-associated IRF6 and/or GRHL3 variants also affect their tumor suppressive functions in vivo, and whether CLP/VWS patients harboring such variants might have an increased risk to develop certain types of carcinomas later in their lives. The gene discussed is IRF6; the disease is neoplasm.